Show simple item record

dc.contributor.authorNagappan, Ren_NZ
dc.contributor.authorFlegel, WAen_NZ
dc.contributor.authorSrivastava, Ken_NZ
dc.contributor.authorWilliams, ECen_NZ
dc.contributor.authorRyzhov, Ien_NZ
dc.contributor.authorTuzikov, Aen_NZ
dc.contributor.authorGalanina, Oen_NZ
dc.contributor.authorShilova, Nen_NZ
dc.contributor.authorSukhikh, Gen_NZ
dc.contributor.authorPerry, Hen_NZ
dc.contributor.authorBovin, NVen_NZ
dc.contributor.authorHenry, SMen_NZ
dc.date.accessioned2021-04-15T22:45:15Z
dc.date.available2021-04-15T22:45:15Z
dc.date.copyright2021en_NZ
dc.identifier.citationTransfusion. 2021; 61: 1171– 1180. https://doi.org/10.1111/trf.16327
dc.identifier.issn1537-2995en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/14122
dc.description.abstractBACKGROUND: The COVID-19 pandemic is having a major global impact, and the resultant response in the development of new diagnostics is unprecedented. The detection of antibodies against SARS-CoV-2 has a role in managing the pandemic. We evaluated the feasibility of using SARS-CoV-2 peptide Kode Technology modified red cells (C19-kodecytes) to develop an assay compatible with existing routine serologic platforms. STUDY DESIGN AND METHODS: A panel of eight unique red cells modified using Kode Technology function-spacer-lipid constructs and bearing short SARS-CoV-2 peptides was developed (C19-kodecyte assay). Kodecytes were tested against undiluted expected antibody negative and positive plasma samples in manual tube and three column agglutination platforms. Parallel analysis with the same peptides in solid phase by enzyme immunoassays was performed. Evaluation samples included >120 expected negative blood donor samples and > 140 COVID-19 convalescent plasma samples, with independent serologic analysis from two centres. RESULTS: Specificity (reaction rate against expected negative samples) in three different column agglutionation (CAT) platforms against novel C19-kodecytes was >91%, which correlated with published literature. Sensitivity (reaction rate against expected positive convalescent, PCR confirmed samples) ranged from 82% to 97%, compared to 77% with the Abbott Architect SARS-CoV-2 IgG assay. Manual tube serology was less sensitive than CAT. Enzyme immuno assay results with some Kode Technology constructs also had high sensitivity. CONCLUSIONS: C19-kodecytes are viable for use as serologic reagent red cells for the detection of SARS-CoV-2 antibody with routine blood antibody screening equipment.en_NZ
dc.languageengen_NZ
dc.publisherWiley
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1111/trf.16327
dc.rights© 2021 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.subjectInfectious disease testing; Intravenous immunoglobulin; Kodecyte
dc.titleCOVID-19 Antibody Screening With SARS-CoV-2 Red Cell Kodecytes Using Routine Serologic Diagnostic Platformsen_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.1111/trf.16327en_NZ
pubs.elements-id398088
aut.relation.journalTransfusionen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record